News

Blood-based screening has acceptable accuracy for colorectal cancer detection
A blood-based test has acceptable accuracy for colorectal cancer detection but not for advanced precancerous lesions in an ...
The American Journal of Managed Care12d
FIT Outperforms Blood-Based cfDNA Test in Detecting Precancerous Colorectal Lesions
Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal ...
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.
A new blood test can tell if cancer has returned months before a scan
New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial information to make decisions about treatment. But more studies are needed ...
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...
Medical Device Network on MSN8d
Guardant Health’s MCD test earns FDA breakthrough designation
Guardant Health's Shield multi-cancer detection (MCD) test has secured the US Food and Drug Administration’s (FDA) ...
The American Journal of Managed Care9d
Blood Test Detects 79% of Colorectal Cancers in Screening Study
A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.